Related Experiment Video
Updated: Jan 16, 2026

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Modeling COVID-19 pneumonia and COVID-associated pulmonary aspergillosis: sensitivity analysis and optimal control
Mallela Ankamma Rao1, Emad K Jaradat2, Medisetty Padma Devi3
1Department of Mathematics & Statistics, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Yadadri, Bhuvanagiri, Telangana, 508284, India.
Abstract:
Severe cases of COVID-19 can progress to pneumonia and, in some patients, to COVID-19-associated pulmonary aspergillosis (CAPA), a fungal co-infection linked to high mortality. Most existing models address COVID-19 transmission alone, without explicitly capturing the sequential progression to pneumonia and CAPA. To address this gap, we develop a novel compartmental model (SIIcpIcaHR) that integrates the co-dynamics of COVID-19 pneumonia and CAPA, incorporating both disease progression pathways and hospitalisation processes. The model is calibrated using cumulative COVID-19 case data from India, and analysed through stability theory, sensitivity analysis, and an optimal control framework. Sensitivity indices and Partial Rank Correlation Coefficients identify key parameters influencing transmission and severity. We evaluate time-dependent intervention strategies-vaccination, early hospitalisation, and enhanced treatment-individually and in combination, using Pontryagin's Maximum Principle and numerical simulation. Results show that while each single measure reduces disease burden, combined application of all three significantly minimises pneumonia and CAPA prevalence, lowers hospitalisation needs, and is cost-effective within realistic constraints. These findings emphasise the importance of integrated public health strategies that couple pharmaceutical and clinical interventions to curb severe COVID-19 outcomes and associated fungal complications.
More Related Videos
10:30Author Spotlight: Developing a Microfluidic Lung-on-Chip Model for In-Depth Study of Human Immune Response and Infection Mechanisms
Published on: May 31, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment